Hypertriglyceridemia

ATLANTA — Plozasiran provided sustained reduction in triglycerides, apolipoprotein C-III and remnant cholesterol out to 48 weeks for patients with severe hypertriglyceridemia, a speaker reported.

ATLANTA — Monthly administration of subcutaneous olezarsen substantially reduced triglyceride levels compared with placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk, according to new phase 2 data.

There are many new treatment strategies for patients with statin intolerance. Finding a regimen that is acceptable to the patient may require switching agents, changing dosages or using alternative regimens, according to experts.

Healio and Cardiology Today have aggregated news you may have missed from the 2023 Cardiometabolic Health Congress in Boston.

After years of failed attempts to develop therapies meant to reduce elevated triglycerides, novel agents are now showing promise in the management of hypertriglyceridemia, a speaker said.

BOSTON — After years of failed clinical trials with agents to lower severely elevated triglycerides, emerging therapeutics hold promise for effectively addressing hypertriglyceridemia and reducing associated CV risks, a speaker reported.

Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported.

In two prospective cohort studies and a meta-analysis of present and past studies, elevated LDL triglycerides were associated with increased risk for atherosclerotic CVD and its components, researchers reported.

CHICAGO — In this Healio exclusive, Manesh R. Patel, MD, FACC, FAHA, FSCAI, provides his perspective on a few of the late-breaking clinical trials presented at the American Heart Association Scientific Sessions.